ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
ImmuCell Corporation (Nasdaq: ICCC), an animal health company focused on dairy and beef cattle products, will announce its Q2 2025 financial results after market close on August 14, 2025. The company will host a conference call on August 15, 2025, at 9:00 AM ET to discuss the results.
ImmuCell manufactures First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal restrictions.
ImmuCell Corporation (Nasdaq: ICCC), un'azienda nel settore della salute animale specializzata in prodotti per bovini da latte e da carne, annuncerà i suoi risultati finanziari del secondo trimestre 2025 dopo la chiusura del mercato il 14 agosto 2025. La società terrà una conference call il 15 agosto 2025 alle 9:00 AM ET per discutere i risultati.
ImmuCell produce First Defense®, che offre Immediate Immunity™ ai vitelli neonati da latte e da carne, e sta sviluppando Re-Tain®, un trattamento innovativo per la mastite subclinica nelle vacche da latte senza restrizioni di scarto del latte o ritiro pre-macellazione richieste dalla FDA.
ImmuCell Corporation (Nasdaq: ICCC), una empresa de salud animal enfocada en productos para ganado lechero y de carne, anunciará sus resultados financieros del segundo trimestre de 2025 después del cierre del mercado el 14 de agosto de 2025. La compañía realizará una conferencia telefónica el 15 de agosto de 2025 a las 9:00 AM ET para discutir los resultados.
ImmuCell fabrica First Defense®, que proporciona Immediate Immunity™ a terneros recién nacidos de ganado lechero y de carne, y está desarrollando Re-Tain®, un tratamiento novedoso para la mastitis subclínica en vacas lecheras sin las restricciones de descarte de leche o retiro pre-sacrificio requeridas por la FDA.
ImmuCell Corporation (Nasdaq: ICCC)는 낙농 및 육우용 가축 제품에 중점을 둔 동물 건강 회사로, 2025년 2분기 재무 결과를 2025년 8월 14일 장 마감 후 발표할 예정입니다. 회사는 2025년 8월 15일 오전 9시(동부 표준시)에 결과를 논의하기 위한 컨퍼런스 콜을 개최합니다.
ImmuCell은 신생 낙농 및 육우 송아지에게 Immediate Immunity™를 제공하는 First Defense®를 제조하며, FDA 요구 사항인 우유 폐기나 도축 전 제한 없이 낙농 암소의 잠복 유선염 치료를 위한 혁신적인 치료제 Re-Tain®을 개발 중입니다.
ImmuCell Corporation (Nasdaq : ICCC), une entreprise spécialisée dans la santé animale avec un focus sur les produits pour bovins laitiers et à viande, annoncera ses résultats financiers du deuxième trimestre 2025 après la clôture des marchés le 14 août 2025. La société tiendra une conférence téléphonique le 15 août 2025 à 9h00 ET pour discuter des résultats.
ImmuCell fabrique First Defense®, offrant Immediate Immunity™ aux veaux nouveau-nés laitiers et à viande, et développe Re-Tain®, un traitement innovant pour la mammite subclinique chez les vaches laitières sans les restrictions de rejet de lait ou de retrait pré-abattage exigées par la FDA.
ImmuCell Corporation (Nasdaq: ICCC), ein Unternehmen im Bereich Tiergesundheit mit Fokus auf Produkte für Milch- und Rindfleischrinder, wird seine Finanzergebnisse für das zweite Quartal 2025 nach Börsenschluss am 14. August 2025 bekannt geben. Das Unternehmen wird am 15. August 2025 um 9:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen.
ImmuCell stellt First Defense® her, das Neugeborenen von Milch- und Fleischrindern Immediate Immunity™ bietet, und entwickelt Re-Tain®, eine neuartige Behandlung der subklinischen Mastitis bei Milchkühen ohne von der FDA vorgeschriebene Milchverwerfung oder Vor-Schlacht-Rückzugsfristen.
- None.
- None.
Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ET
PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2025 after the market closes on Thursday, August 14, 2025.
The Company is planning to host a conference call the next morning, Friday, August 15, 2025, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until August 22, 2025 at (877) 344-7529 (toll free) or (412) 317-0088 (international), utilizing replay access code #5659118.
The Company anticipates no change to the preliminary sales results for the second quarter ended June 30, 2025 that were disclosed on July 9, 2025. The Company expects to file its Quarterly Report on Form 10-Q on Thursday, August 14, 2025 after the market closes.
Investors are encouraged to review the Company’s updated Corporate Presentation slide deck that provides an overview of the Company’s business which can be accessed under the “Investors” tab of the Company’s website at www.immucell.com, or by request to the Company. An updated version of the slide deck will be made available after the market closes on Thursday, August 14, 2025.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef calves. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO Timothy C. Fiori, Chief Financial Officer ImmuCell Corporation (207) 878-2770 |
| Joe Diaz, Robert Blum and Joe Dorame Lytham Partners, LLC (602) 889-9700 iccc@lythampartners.com |
FAQ
When will ImmuCell (ICCC) release Q2 2025 earnings?
How can investors join ImmuCell's Q2 2025 earnings call?
What products does ImmuCell (ICCC) manufacture?
Where can investors access ImmuCell's corporate presentation?
